Helen Hobbs

from Wikipedia, the free encyclopedia

Helen Haskell Hobbs (born May 5, 1952 in Boston , Massachusetts ) is an American geneticist and metabolism researcher at the University of Texas Southwestern Medical Center in Dallas . She is considered a leader in the genetics of hypercholesterolemia and dyslipoproteinemia .

Life

Hobbs began her studies at the University of Pennsylvania , graduating from Stanford University with a bachelor's degree in human biology in 1974 and an MD in medicine from Case Western Reserve University School of Medicine in 1979 . She completed her residency in internal medicine at Columbia-Presbyterian Medical Center in New York City , Parkland Memorial Hospital and the University of Texas Southwestern Medical Center (UTD), both in Dallas . In 1983 she received board certification for internal medicine and in 1986 for endocrinology and metabolic medicine . From 1983 to 1987 she worked as a postdoctoral fellow with Michael Brown and Joseph Goldstein in the Department of Molecular Genetics at the UTD.

In 1987 Hobbs received a first professorship (assistant professor) for internal medicine and molecular genetics at the UTD, in 1991 she became an associate professor , and since 1995 she has been a full professor. Since 2000 she has been director of the McDermott Center for Human Growth and Development at UTD. She runs her research laboratory together with nutritionist Jonathan C. Cohen .

Hobbs has also been doing research for the Howard Hughes Medical Institute since 2002 . Since 2009 she has been on the board of directors of the pharmaceutical company Pfizer Inc., and since 2011 she has worked in an advisory capacity for the biotechnology company Regeneron Pharmaceuticals .

Hobbs is married and has two children.

Act

Hobbs studies the genetics of cholesterol metabolism . She tries to identify people who are at increased risk of atherosclerosis . The aim is to develop new therapy options, for example to reduce the frequency of heart attacks .

Hobbs clarified the genetic causes of sitosterolemia ( ABCG5 / ABCG8 ), autosomal recessive hypercholesterolemia (ARH) and dominant hypercholesterolemia ( PCSK9 ). She was able to show that a large number of individually rare variations in the gene sequence together lead to a considerable range of variation in the expression of metabolic disorders. Using genetic data, she was able to show that the level of LDL cholesterol has the greatest influence on the risk of developing coronary heart disease .

Hobbs' other work deals with the influence of variations of PNPLA3 on the development of fatty liver and liver damage.

Awards (selection)

Web links

Individual evidence

  1. ^ List of Public Companies Worldwide, Letter - Businessweek. In: bloomberg.com. Retrieved October 18, 2015 .
  2. ↑ 2005: Prof. Helen Hobbs - Heinrich Wieland Prize - Homepage. In: heinrich-wieland-prize.de. November 4, 2005, accessed October 18, 2015 .
  3. ↑ Book of Members 1780 – present (PDF; 777 kB) at the American Academy of Arts and Sciences (amacad.org); Retrieved October 18, 2015.
  4. ↑ Helen Hobbs. In: nasonline.org. Retrieved October 18, 2015 .
  5. ^ The Pearl Meister Greengard Prize - The Rockefeller University. In: greengardprize.rockefeller.edu. Retrieved October 18, 2015 .
  6. ↑ 2016 Passano Award recognizes groundbreaking cholesterol research by geneticists Hobbs, Cohen: May 2016 News Releases - UT Southwestern, Dallas, Texas. In: utsouthwestern.edu. May 13, 2016, accessed May 14, 2016 .
personal data
SURNAME Hobbs, Helen
ALTERNATIVE NAMES Hobbs, Helen Haskell; Hobbs, Helen H.
BRIEF DESCRIPTION American geneticist
DATE OF BIRTH May 5th 1952
PLACE OF BIRTH Boston , Massachusetts